We searched MEDLINE, PubMed, and Cochrane Central electronic databases and collected studies of patients with MCFACs treated with 1 of 3 surgical methods. Eligible studies reported the rate of clinical symptoms improvement (RCSI), rate of cyst reduction (RCR), rate of total complications (RTC), rate of short-term complications (RSTC), rate of long-term complications (RLTC), and other parameters.
Eighteen studies met the criteria. MCFACs were divided into 3 groups on the basis of surgical method: RCSI in group I (237 patients, neuroendoscopic fenestration) was 90% (95% confidence interval [CI]: 83%–95%); RCR: 76% (95% CI: 67%–84%); RTC: 28% (95% CI: 22%–34%); RSTC: 23% (95% CI: 17%–30%); and RLTC: 6% (95% CI: 3%–11%). RCSI in group II (144 patients, microsurgical fenestration) was 87% (95% CI: 75%–96%); RCR: 87% (95% CI: 70%–97%); RTC: 49% (95% CI: 30%–68%); RSTC: 44% (95% CI: 21%–68%); RLTC: 3% (95% CI: 0%–12%). RCSI in group III (93 patients, cystoperitoneal shunting) was 93% (95% CI: 66%–99%); RCR: 93% (95% CI: 66%–99%); RTC: 20% (95% CI: 5%–42%); RSTC: 10% (95% CI: 0%–31%); RLTC: 15% (95% CI: 9%–23%). RLTC differed significantly between the 3 groups (P = 0.005); RTC and RSTC between group I and group II (P = 0.002).
All 3 surgical methods are effective for MCFACs, but considering safety, neuroendoscopic fenestration may be the best initial procedure.